Polyrizon

Polyrizon EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Polyrizon (PLRZ) as of Oct 21, 2026 is -5.95 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.43 M USD — a change of 317.18% (lower).

EBITDA

-5.95 MUSD

YoY

317.18%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Polyrizon is 2025 -5.95 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Polyrizon was 2024 -1.43 M USD. It decreases by 317.18% lower compared to the previous year.

The Polyrizon EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-72,000.00 USD
Jan 1, 2021
-703,000.00 USD
Jan 1, 2022
-895,000.00 USD
Jan 1, 2023
-635,000.00 USD
Jan 1, 2024
-1.43 M USD
Jan 1, 2025
-5.95 M USD
The Polyrizon EBITDA history
YEAREBITDAYoY
-5.95 MUSD+317.18%
-1.43 MUSD+124.57%
-635,000.00USD-29.05%
-895,000.00USD+27.31%
-703,000.00USD+876.39%
-72,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Polyrizon is -5.95 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Polyrizon changed from -1.43 M USD to -5.95 M USD, representing a 317.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Polyrizon since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Polyrizon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Polyrizon

All Key Metrics — Polyrizon